We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Smart Pills Offer Diagnostic Tool for Gut Disorders

By LabMedica International staff writers
Posted on 08 May 2017
Print article
Image: Recent phase-I clinical trials suggest that smart pills may have potential to revolutionize diagnosis and prevention of several gut disorders (Photo courtesy of RMIT University).
Image: Recent phase-I clinical trials suggest that smart pills may have potential to revolutionize diagnosis and prevention of several gut disorders (Photo courtesy of RMIT University).
Researchers have completed successful phase-one human clinical trials of ingestible capsules (the size of a vitamin pill) that have potential to revolutionize diagnosis and prevention of gastrointestinal (GI) disorders and diseases.

Researchers at RMIT University (Melbourne, Australia), led by the pills’ co-inventor Prof. Kourosh Kalantar-zadeh, tested the ingestible smart capsules that journey through and measure gas levels in the GI tract. The human trials were undertaken with colleagues from Monash University. “We have been lucky to have Monash medical academics helping us on this journey,” said Prof. Kalantar-zadeh, “Without their input we would not be able to proceed.”

RMIT is one of the leading universities researching the development of ingestible sensors, a technology that has demonstrated several 1000s-times more sensitivity to gut gases than current alternative techniques. “Currently, one of the only methods for diagnosing gut disorders, such as mal-absorption of carbohydrates, irritable bowel syndrome, and inflammable bowel disease, is to measure hydrogen concentrations in the breath,” said Prof. Kalantar-zadeh, “However, breath tests are mired by a lack of sensitivity and specificity and are unable to provide the necessary gold standard for diagnosis.”

Co-inventor Dr. Kyle Berean said, “Ingestible sensors also offer a reliable diagnostic tool for colon cancer, meaning that people won’t have to undergo colonoscopies in future.”

A key finding from the initial trials was on the safety of the new technology: “Smart pills are harmless and there is no risk of capsule retention,” said Dr. Berean. An added advantage is that the capsules can be synched with smartphones, meaning results are easily accessible by users and doctors online. There are also many potential applications for this technology.

“The sensors allow us to measure all the fluids and gases in the gut, giving us a multidimensional picture of the human body,” said Prof. Kalantar-zadeh, “Gas sensing is just the beginning.”

A paper by the Centre for Advanced Electronics and Sensors (CADES) research team outlining the future of ingestible sensors was published in the April 2017 issue of the journal ACS Sensors. Outcomes of the human trials were presented at Digestive Disease Week (DDW; Chicago, IL, USA, May 6-9, 2017).

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.